Abstract
Background
Fecal calprotectin has been extensively investigated as a screening marker for the detection of necrotizing enterocolitis (NEC). However, there is a complete lack of consensus regarding its efficacy as a diagnostic test.
Objective
The purpose of the present systematic review is to evaluate the effectiveness of fecal calprotectin as a screening marker for the detection of NEC.
Materials and methods
We conducted a systematic review of studies published in the Medline (1966–2016), Scopus (2004–2016), ClinicalTrials.gov (2008–2016), Cochrane Central Register of Controlled Trials CENTRAL (1999–2016), and Google Scholar (2004–2016) databases, combined with studies found in the reference lists of the included studies. All prospective and retrospective observational cohort studies were included.
Results
Thirteen studies that included 601 neonates were identified in the international literature. The presence and severity of NEC was evaluated with the modified Bell’s criteria. Ten studies found significantly elevated fecal calprotectin levels among infants with NEC (p < 0.05). One study found that this effect was observed irrespective of the stage of the disease. Five studies evaluated the efficacy of fecal calprotectin as a diagnostic test. The reported sensitivity ranged between 76 and 100 %, and the specificity varied from 39 to 96.4 %. However, the proposed cut-off values were not similar.
Conclusion
Current evidence suggests that fecal calprotectin is elevated in newborns suffering from NEC. However, its significance as an early screening marker remains unknown. Future studies are needed and should focus on the identification of specific cut-off values.
Similar content being viewed by others
References
Fitzgibbons SC, Ching Y, Yu D, Carpenter J, Kenny M, Weldon C, et al. Mortality of necrotizing enterocolitis expressed by birth weight categories. J Pediatr Surg. 2009;44:1072–5 (discussion 1075–6).
Thompson AM, Bizzarro MJ. Necrotizing enterocolitis in newborns: pathogenesis, prevention and management. Drugs. 2008;68:1227–38.
Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg. 1978;187:1–7.
Moss RL, Dimmitt RA, Barnhart DC, Sylvester KG, Brown RL, Powell DM, et al. Laparotomy versus peritoneal drainage for necrotizing enterocolitis and perforation. N Engl J Med. 2006;354:2225–34.
Young C, Sharma R, Handfield M, Mai V, Neu J. Biomarkers for infants at risk for necrotizing enterocolitis: clues to prevention? Pediatr Res. 2009;65:91R–7R.
Oh S, Young C, Gravenstein N, Islam S, Neu J. Monitoring technologies in the neonatal intensive care unit: implications for the detection of necrotizing enterocolitis. J Perinatol Off J Calif Perinat Assoc. 2010;30:701–8.
Striz I, Trebichavsky I. Calprotectin—a pleiotropic molecule in acute and chronic inflammation. Physiol Res Acad Scientiarum Bohemoslov. 2004;53:245–53.
Thuijls G, Derikx JP, van Wijck K, Zimmermann LJ, Degraeuwe PL, Mulder TL, et al. Non-invasive markers for early diagnosis and determination of the severity of necrotizing enterocolitis. Ann Surg. 2010;251:1174–80.
Burri E, Beglinger C. Faecal calprotectin—a useful tool in the management of inflammatory bowel disease. Swiss Med Wkly. 2012;142:w13557.
Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:524–34.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:e1–34.
Wells GA, Shea B, O`Connel D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. 2011. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 27 Nov 2015.
Carroll D, Corfield A, Spicer R, Cairns P. Faecal calprotectin concentrations and diagnosis of necrotising enterocolitis. Lancet. 2003;361:310–1.
Altamimi EM, Murthy P, Urbaniak C, Grey VL, Denou E, Issenman R. Prospective non-randomized diagnostic pilot study using fecal calprotectin for diagnosing necrotizing enterocolitis (NEC) in very low birth weight infants. Gastroenterology. 2011;140:S-685–6.
Aydemir G, Cekmez F, Tanju IA, Canpolat FE, Genc FA, Yildirim S, et al. Increased fecal calprotectin in preterm infants with necrotizing enterocolitis. Clin Lab. 2012;58:841–4.
Aydemir O, Aydemir C, Sarikabadayi YU, Emre Canpolat F, Erdeve O, Biyikli Z, et al. Fecal calprotectin levels are increased in infants with necrotizing enterocolitis. J Matern Fetal Neonatal Med. 2012;25:2237–41.
Reisinger KW, Van der Zee DC, Brouwers HA, Kramer BW, van Heurn LW, Buurman WA, et al. Noninvasive measurement of fecal calprotectin and serum amyloid A combined with intestinal fatty acid-binding protein in necrotizing enterocolitis. J Pediatr Surg. 2012;47:1640–5.
Terrin G, Passariello A, De Curtis M, Paludetto R, Berni Canani v. S100 A8/A9 protein as a marker for early diagnosis of necrotising enterocolitis in neonates. Arch Dis Child. 2012;97:1102.
Albanna EA, Ahmed HS, Awad HA. Stool calprotectin in necrotizing enterocolitis. Journal Clin Neonatol. 2014;3:16–9.
Selimoglu MA, Temel I, Yildirim C, Ozyaln F, Aktas M, Karabiber H. The role of fecal calprotectin and lactoferrin in the diagnosis of necrotizing enterocolitis. Pediatr Crit Care Med. 2012;13:452–4.
Yoon JM, Park JY, Ko KO, Lim JW, Cheon EJ, Kim HJ. Fecal calprotectin concentration in neonatal necrotizing enterocolitis. Korean J Pediatr. 2014;57:351–6.
Fagerberg UL, Loof L, Merzoug RD, Hansson LO, Finkel Y. Fecal calprotectin levels in healthy children studied with an improved assay. J Pediatr Gastroenterol Nutr. 2003;37:468–72.
Bin-Nun A, Booms C, Sabag N, Mevorach R, Algur N, Hammerman C. Rapid fecal calprotectin (FC) analysis: point of care testing for diagnosing early necrotizing enterocolitis. Am J Perinatol. 2015;32:337–42.
Shenoy M, Shenoy KT, Roseth A, Geir L, Keshavamurthy SR. Diagnostic utility of fecal calprotectin as a biomarker of gut inflammation in neonates to predict necrotizing enterocolitis: a prospective study. Indian J Child Health. 2014;1:99–104.
Avula S, Nantais-Smith L, Monga R, Lockwood L, Lansing E, Kadrofske M. Stool biomarkers to diagnose necrotizing enterocolitis in preterm infants: a pilot case-control study. AAP National Conference and Exhibition October 23–27, 2015.
Shenoy MT, Shenoy KT, Roseth A, Geir L, Keshavamurthy SR. Diagnostic utility of fecal calprotectin as a biomarker of gut inflammation in neonates to predict necrotizing enterocolitis: a prospective study. Indian J Child Health. 2014;1:99–104.
Tang WH, Guan MC, Jiang XJ, Teng CZ, Wang HT. The clinical significance of fecal calprotectin on premature infant with necrotizing enterocolitis. Chin J Health Lab Technol. 2013;4:23–8.
Altamimi EM, Murthy P, Urbaniak C, Grey VL, Denou E, Issenman R. Prospective non-randomized diagnostic pilot study using fecal calprotectin for diagnosing necrotizing enterocolitis (NEC) in very low birth weight infants. Gastroenterology. 2011;140:S-685–6.
Avula S, LN-S, Monga R, Lockwood L, Kadrofske M. Stool biomarkers to diagnose necrotizing enterocolitis in preterm infants: a pilot case-control study. American Academy of Pediatrics. Washington, DC; 24–27 Oct 2015.
Elgin TG, Kern SL, McElroy SJ. Development of the neonatal intestinal microbiome and its association with necrotizing enterocolitis. Clin Ther. 2016;38:706–15.
Erbayrak M, Turkay C, Eraslan E, Cetinkaya H, Kasapoglu B, Bektas M. The role of fecal calprotectin in investigating inflammatory bowel diseases. Clinics (Sao Paulo, Brazil). 2009;64:421–5.
Isaksen B, Fagerhol MK. Calprotectin inhibits matrix metalloproteinases by sequestration of zinc. Mol Pathol MP. 2001;54:289–92.
Polycarpou E, Zachaki S, Papaevangelou V, Tsolia M, Kyriacou A, Kostalos C, et al. Oral l-arginine supplementation and faecal calprotectin levels in very low birth weight neonates. J Perinatol Off J Calif Perinat Assoc. 2013;33:141–6.
Laforgia N, Baldassarre ME, Pontrelli G, Indrio F, Altomare MA, Di Bitonto G, et al. Calprotectin levels in meconium. Acta Paediatr (Oslo, Norway 1992). 2003;92:463–6.
Campeotto F, Baldassarre M, Butel MJ, Viallon V, Nganzali F, Soulaines P, et al. Fecal calprotectin: cutoff values for identifying intestinal distress in preterm infants. J Pediatr Gastroenterol Nutr. 2009;48:507–10.
Yang Q, Smith PB, Goldberg RN, Cotten CM. Dynamic change of fecal calprotectin in very low birth weight infants during the first month of life. Neonatology. 2008;94:267–71.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
The authors have no conflicts of interest to report.
Research involving human participants and/or animals
This is a systematic review of data already published in this field. In the present study we did not have direct involvement with humans or animals.
Informed consent
Not applicable because this study did not include individual patient data.
Additional information
Responsible Editor: John Di Battista.
Rights and permissions
About this article
Cite this article
Pergialiotis, V., Konstantopoulos, P., Karampetsou, N. et al. Calprotectin levels in necrotizing enterocolitis: a systematic review of the literature. Inflamm. Res. 65, 847–852 (2016). https://doi.org/10.1007/s00011-016-0963-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00011-016-0963-9